​

Tango Therapeutics Ownership | Who Owns Tango Therapeutics?

OverviewForecastRevenueFinancialsChart

Tango Therapeutics Ownership Summary

Tango Therapeutics is owned by 59.28% institutional investors, 1.38% insiders, and 39.35% retail investors. Farallon capital management is the largest institutional shareholder, holding 9.73% of TNGX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.91% of its assets in Tango Therapeutics shares.

TNGX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTango Therapeutics59.28%1.38%39.35%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Farallon capital management10.76M9.73%$90.36M
Ecor1 capital10.63M9.62%$89.30M
Boxer capital management9.77M8.84%$82.08M
Tcg crossover management8.54M7.72%$71.70M
Blackrock funding, inc. /de8.54M7.70%$75.67M
Boxer capital8.20M7.58%$70.34M
Trv gp iv7.87M7.10%$69.77M
Vanguard group6.75M6.08%$59.81M
Woodline partners lp6.03M5.45%$50.65M
Siren5.88M5.32%$49.42M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Trv gp iv7.87M27.35%$69.77M
Boxer capital management9.77M26.16%$82.08M
Nextech invest5.53M7.08%$46.49M
Ecor1 capital10.63M4.29%$89.30M
Boxer capital8.20M3.70%$70.34M
Tcg crossover management8.54M3.53%$71.70M
Nextech invest5.53M2.77%$17.10M
Allostery investments lp40.00K2.61%$204.80K
Siren5.88M1.93%$49.42M
Bain capital life sciences investors2.71M1.51%$22.78M

Top Buyers

HolderShares% AssetsChange
Goldman sachs group4.94M0.01%3.43M
Paradigm biocapital advisors lp3.09M0.74%3.09M
Point72 asset management2.92M0.04%2.92M
Blackrock funding, inc. /de8.54M0.00%2.89M
Siren5.88M1.93%2.52M

Top Sellers

HolderShares% AssetsChange
Trv gp iv7.87M27.35%-5.99M
Southpoint capital advisors lp---5.00M
Gilead sciences---4.85M
Adage capital partners gp2.51M0.03%-3.39M
Tcg crossover management8.54M3.53%-2.20M

New Positions

HolderShares% AssetsChangeValue
Paradigm biocapital advisors lp3.09M0.74%3.09M$25.92M
Point72 asset management2.92M0.04%2.92M$24.52M
Deep track capital, lp1.45M0.34%1.45M$12.22M
Logos global management lp950.00K0.72%950.00K$7.98M
Avoro capital advisors545.00K0.06%545.00K$4.58M

Sold Out

HolderChange
Twin peaks wealth advisors-1.00
Nelson, van denburg & campbell wealth management group-12.00
True wealth design-16.00
Versant capital management-28.00
Us bancorp \de\-53.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025103-28.97%65,776,312-53.01%590.37%79-8.14%13-61.76%
Sep 30, 202514117.50%131,410,6723.26%1180.90%8421.74%3317.86%
Jun 30, 2025118-127,240,30347.81%1151.89%6715.52%28-28.21%
Mar 31, 2025121-11.68%107,289,0950.80%971.01%59-28.92%3840.74%
Dec 31, 202471-41.80%37,625,298-62.92%340.40%41-25.45%13-63.89%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.91M2.91%-
State Street® SPDR® S&P® Biotech ETF3.91M2.90%-20.92K
Fidelity Growth Compy Commingled Pl S2.42M2.25%712.74K
iShares Russell 2000 ETF2.55M1.89%1.66M
Fidelity Growth Compy Commingled Pl O1.69M1.58%-
Fidelity Growth Company Fund1.53M1.43%543.72K
T. Rowe Price Small-Cap Value1.54M1.39%-117.06K
Fidelity Small Cap Growth1.25M1.17%-
T. Rowe Price US Small-Cap Core Equity1.19M1.11%277.63K
T. Rowe Price Small-Cap Stock1.19M1.11%199.50K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 05, 2026Crystal Adam President, R&DSell$303.76K
Feb 25, 2026Crystal Adam President, R&DSell$694.21K
Feb 03, 2026Beckman Daniella Chief Financial OfficerSell$125.07K
Feb 03, 2026Beckman Daniella Chief Financial OfficerSell$1.46K
Feb 03, 2026Weber Barbara Director, Executive ChairSell$370.00K

Insider Transactions Trends

DateBuySell
2026 Q1-7
2025 Q4-1
2025 Q3-6
2025 Q2--
2025 Q1-8

TNGX Ownership FAQ

Who Owns Tango Therapeutics?

Tango Therapeutics shareholders are primarily institutional investors at 59.28%, followed by 1.38% insiders and 39.34% retail investors. The average institutional ownership in Tango Therapeutics's industry, Biotech Stocks , is 381.47%, which Tango Therapeutics falls below.

Who owns the most shares of Tango Therapeutics?

Tango Therapeutics’s largest shareholders are Farallon capital management (10.76M shares, 9.73%), Ecor1 capital (10.63M shares, 9.62%), and Boxer capital management (9.77M shares, 8.84%). Together, they hold 28.19% of Tango Therapeutics’s total shares outstanding.

Does Blackrock own Tango Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Tango Therapeutics.

Who is Tango Therapeutics’s biggest shareholder by percentage of total assets invested?

Trv gp iv is Tango Therapeutics’s biggest shareholder by percentage of total assets invested, with 27.35% of its assets in 7.87M Tango Therapeutics shares, valued at 69.77M$.

Who is the top mutual fund holder of Tango Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Tango Therapeutics shares, with 2.91% of its total shares outstanding invested in 3.91M Tango Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools